This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • ciclesonide is a once daily, inhaled corticosteroid delivered via a hydrofluoroalkane (non-CFC) metered-dose inhaler, licensed for the prophylactic treatment of persistent asthma in adults
  • is converted to the active metabolite in the lungs and has low systemic bioavailability, therefore it has a lower potential for systemic adverse effects
  • in short term studies ciclesonide caused less suppression of cortisol release compared with budesonide or fluticasone, but there is no evidence that this translates into fewer long-term (>52 weeks) adverse effects
  • evidence indicates that it is of equivalent efficacy to existing inhaled steroids (budesonide and fluticasone) in the management of mild-to-moderate asthma, but long-term data on clinical outcomes such as exacerbations, hospitalisations and quality of life are unavailable
  • promoted for its relative lack of local adverse effects, and convenience to the patient (once-daily administration). It may help patients who do not comply with regular inhaled corticosteroid therapy
  • not licensed to use in children under the age of 12 years (2)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.